Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Invested Capital (2019 - 2025)

Harmony Biosciences Holdings' Invested Capital history spans 7 years, with the latest figure at $890.2 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 31.81% year-over-year to $890.2 million; the TTM value through Dec 2025 reached $890.2 million, up 31.81%, while the annual FY2025 figure was $890.2 million, 31.81% up from the prior year.
  • Invested Capital for Q4 2025 was $890.2 million at Harmony Biosciences Holdings, up from $855.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $890.2 million in Q4 2025 and bottomed at $154.0 million in Q3 2021.
  • The 5-year median for Invested Capital is $489.1 million (2023), against an average of $488.2 million.
  • The largest YoY upside for Invested Capital was 167.56% in 2021 against a maximum downside of 47.71% in 2021.
  • A 5-year view of Invested Capital shows it stood at $188.5 million in 2021, then surged by 114.76% to $404.8 million in 2022, then increased by 19.06% to $482.0 million in 2023, then skyrocketed by 40.13% to $675.4 million in 2024, then surged by 31.81% to $890.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Invested Capital are $890.2 million (Q4 2025), $855.1 million (Q3 2025), and $791.8 million (Q2 2025).